Is BRIUMVI’s Trial in Treatment-Resistant Schizophrenia Altering The Investment Case For TG Therapeutics (TGTX)?
TG Therapeutics has initiated a Phase 2 trial for BRIUMVI in treatment-resistant schizophrenia, aiming to expand its B-cell-targeting drug beyond multiple sclerosis into a new psychiatric indication. While this scientifically interesting move broadens BRIUMVI's potential, the article suggests it's not a major near-term catalyst compared to the development of subcutaneous BRIUMVI for MS. The core investment case for TG Therapeutics remains heavily dependent on its anti-CD20 franchise, with significant near-term focus on expanding into the self-administered market and managing payer scrutiny.
TG Therapeutics, Inc. Stock 12‑Month Price Target Raised to $52.14, Implies 6% Downside
Analysts have raised the average 12-month price target for TG Therapeutics, Inc. (TGTX) stock to $52.14, up from $51.71, with individual forecasts ranging from $20 to $83 per share. Despite this increase, the updated target suggests a potential 6% downside based on the July 6 closing price. The consensus rating for TGTX remains a "Buy" from 8 analysts, with a breakdown of 6 Buys, 1 Hold, and 1 Sell.
TG Therapeutics Announces Initiation of Phase 2 Trial
TG Therapeutics has initiated a Phase 2 clinical trial to evaluate BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study aims to determine if B-cell depletion, a mechanism of action for BRIUMVI, can improve symptoms in patients who haven't responded to standard antipsychotic treatments, based on emerging evidence linking immune dysfunction to schizophrenia. This trial could expand the potential utility of BRIUMVI, which is currently approved for multiple sclerosis, into an area of significant unmet medical need.
TG Therapeutics begins schizophrenia Phase 2 trial
TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label, multicenter study of BRIUMVI (ublituximab-xiiy) for treatment-resistant schizophrenia. The trial involves approximately 60 adult participants who will receive BRIUMVI alongside standard antipsychotic therapy. The primary goal is to assess a minimum 20% reduction in the PANSS score by Week 12, expanding BRIUMVI's potential indications into neuropsychiatric diseases.
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics (NASDAQ:TGTX) has initiated a Phase 2, open-label trial to assess the efficacy and safety of BRIUMVI (ublituximab-xiiy) in approximately 60 adults with treatment-resistant schizophrenia. The study will combine intravenous BRIUMVI with standard antipsychotic therapy, with the primary goal of achieving at least a 20% reduction in PANSS total score by Week 12. This venture aims to explore the potential of B-cell depletion in addressing unmet medical needs in schizophrenia, leveraging BRIUMVI's established safety profile and B-cell depleting capabilities.
TGTX - TG Therapeutics Inc Dividends
This article provides a detailed financial overview of TG Therapeutics Inc (TGTX), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as P/E, EPS, sales growth, and insider/institutional ownership, alongside dividend information which appears to be currently absent. The data presented offers a comprehensive snapshot of the company’s financial health and market position.
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
TG Therapeutics' drug Briumvi has shown strong sales growth, with Q1 2026 sales reaching $201.3 million, and Q2 net sales in the U.S. projected at $220 million. The company faces stiff competition in the multiple sclerosis market from established players like Roche and Novartis, but is exploring label expansions for Briumvi in other autoimmune diseases. TG Therapeutics shares have significantly outperformed the industry year-to-date, and analyst estimates for its 2026 and 2027 earnings per share have risen.
Price to sales forward of TG Therapeutics, Inc. – NASDAQ:TGTX
This article provides the "Price to sales forward" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It lists the period, value, change, and change percentage for this financial indicator. The content is presented as a singular data point within a financial overview for the company.
Price to earnings forward of TG Therapeutics, Inc. – MIL:1TGTX
This article displays the "Price to earnings forward" value for TG Therapeutics, Inc. (MIL:1TGTX). It indicates that the market is currently closed with no trades. The article also provides a list of data providers and copyright notices.
Does TG Therapeutics (NASDAQ:TGTX) Deserve A Spot On Your Watchlist?
This article evaluates TG Therapeutics' stock (NASDAQ: TGTX) as a potential investment by analyzing its financial health, growth prospects, and valuation. It highlights the company's strong revenue growth, positive shareholder returns over the past year, and relatively low debt. The analysis suggests TGTX could be an interesting option for investors seeking growth.
Responsive Playbooks and the TGTX Inflection
This article provides an in-depth analysis of Tg Therapeutics Inc. (NASDAQ: TGTX) based on AI models from Stock Traders Daily. It highlights strong near and mid-term sentiment, compelling upside potential due to no resistance levels above current price, and offers three distinct trading strategies including position trading, momentum breakout, and risk hedging. The analysis also covers multi-timeframe signal analysis with support and resistance levels.
Price to earnings forward of TG Therapeutics, Inc. – NASDAQ:TGTX
This article displays the "Price to earnings forward" metric for TG Therapeutics, Inc. (NASDAQ: TGTX). It indicates the value and change percentage for a specified period and is presented within the context of TradingView's financial data. The information is sourced from ICE Data Services and FactSet.
Enterprise value to EBITDA forward of TG Therapeutics, Inc. – FWB:NKB2
The article provides financial information for TG Therapeutics, Inc. (NKB2) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades recorded at the time of publication. The content also lists various features and services offered by TradingView, the platform hosting this financial data.
Enterprise value to EBIT forward of TG Therapeutics, Inc. – NASDAQ:TGTX
The article discusses the enterprise value to EBIT forward of TG Therapeutics, Inc. (NASDAQ: TGTX). It presents a financial metric within the context of the company's profile on TradingView, which provides market data and financial tools. The content primarily focuses on the display of this specific financial ratio for TGTX.
TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious
TG Therapeutics (TGTX) has seen significant share price gains recently, prompting a re-evaluation of its valuation. While the most followed narrative suggests the stock is currently 4% overvalued at $51.71, Simply Wall St's DCF model indicates a fair value of $207.76, suggesting a 74% discount. This discrepancy highlights differing views on the company's intrinsic value, with factors like revenue expansion, profit margins, and specific drug performance influencing the diverse analyst targets.
TGTX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for TG Therapeutics, Inc. (TGTX) stock, based on analyst opinions and recent financial performance. It includes current stock price, historical data, earnings reports, revenue figures, and market capitalization, along with frequently asked questions about the company's financials and stock performance.
Enterprise value to revenue forward of TG Therapeutics, Inc. – LSX:A1JXW7
This article provides metadata for TG Therapeutics, Inc. (LSX:A1JXW7) focusing on its enterprise value to revenue forward. It indicates the stock is traded on the Lang & Schwarz Exchange and shows the market is currently closed with no recent trades. The content primarily highlights financial metrics and market data access provided by various financial services.
TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35%
The article reports that TG Therapeutics stock has experienced a 10-day winning streak, resulting in a 35% increase in its stock price. The content is very brief and primarily consists of navigation and site information for Trefis.
TG Therapeutics Stock Surges 35%, With A 10-Day Winning Spree
TG Therapeutics (TGTX) has experienced a 10-day winning spree, with its stock surging 35% and its market cap increasing by $2.1 billion to $7.9 billion. The company, a developer of B-cell malignancy drugs and immunotherapies, is considered "Fairly Priced" despite its high valuation due to strong operating performance. The article highlights TGTX's returns against the S&P 500 over various periods and provides key financial data for the last two fiscal years and quarters.
TG Therapeutics Stock 9-Day Winning Spree: Stock Climbs 33%
TG Therapeutics (TGTX) has experienced a 9-day winning streak, with its stock climbing 33% and market cap surging by $1.9 billion to $7.7 billion. Despite this rapid gain, the company's strong operating performance and financial condition suggest it is fairly priced. The article highlights that these significant gains are already priced into the market and emphasizes the importance of predictive signals for future investment decisions.
TG Therapeutics (TGTX) Is Up 7.5% After Positive Subcutaneous BRIUMVI MG Data And Phase 2 Launch – Has The Bull Case Changed?
TG Therapeutics (TGTX) saw a 7.5% increase in its stock price following positive Phase 1 data for its subcutaneous BRIUMVI in myasthenia gravis, demonstrating similar exposure to the IV regimen and symptomatic improvements. The company has also initiated a Phase 2 trial for BRIUMVI in myasthenia gravis as a maintenance therapy, aiming to expand its use beyond multiple sclerosis. This strategic move could significantly alter TG Therapeutics' investment narrative, which has primarily focused on its MS applications.
TG Therapeutics stock hits 52-week high at 54.04 USD
TG Therapeutics (TGTX) stock has reached a 52-week high of $54.04, reflecting a 52.54% increase over the past year and 72.76% year-to-date in 2026. Despite a recent earnings miss, the company shows strong growth, with ongoing clinical trials for BRIUMVI in myasthenia gravis and multiple sclerosis contributing to positive investor sentiment. InvestingPro analysis indicates the stock is undervalued and analysts have revised earnings upwards.
TG Therapeutics stock hits 52-week high at 54.04 USD By Investing.com
TG Therapeutics (TGTX) stock reached a new 52-week high of $54.04, reflecting significant investor confidence and strong performance, with a 72.76% year-to-date return in 2026. Despite a Q1 2026 earnings miss, the company has several ongoing clinical developments for BRIUMVI in myasthenia gravis and multiple sclerosis, which contribute to its positive market sentiment. Analysts have also revised earnings upwards, and the stock is considered undervalued by InvestingPro.
TG Therapeutics Inc (TGTX) Institutional Confidence
TG Therapeutics Inc (TGTX) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 80.02%, showing a 23.29% quarter-over-quarter increase. BlackRock Institutional Trust Company, N.A. is the largest institutional shareholder with 19.14M shares.
TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
TG Therapeutics Inc (TGTX) has an earnings forecast score of 7.56, ranking 99th out of 157 in the Pharmaceuticals industry. Analysts have an average price target of $49.00 for TGTX, with a majority recommending a "Buy" trend. The company's expected revenue for the next quarter is $228.10 million, and its EPS for the prior quarter was $0.17, while the next quarter is projected at $0.36.
TG Therapeutics Stock Surges 28%, With A 8-Day Winning Spree
TG Therapeutics (TGTX) has experienced an 8-day winning streak, with its market cap surging by $1.6 billion and cumulative gains amounting to 28%. Despite the significant rise, the stock is considered fairly priced due to its strong operating performance and financial condition. The article presents historical return data for TGTX compared to the S&P 500 and highlights key financial metrics for the company.
TG Therapeutics Stock Surges 28%, With A 8-Day Winning Spree
TG Therapeutics (TGTX) has experienced an 8-day winning streak, with cumulative gains of 28% and its market cap increasing by $1.6 billion to $7.4 billion. Despite its high valuation, Trefis considers the stock fairly priced due to strong operating performance. The article highlights TGTX's superior returns compared to the S&P 500 across various periods, alongside its recent financial performance.
TG Therapeutics (TGTX) director awarded 8,325 Stock Tracking Units in Form 4 filing
TG Therapeutics director Daniel Hume was granted 8,325 Stock Tracking Units (STUs) as part of a compensation package, as detailed in a recent Form 4 filing. These STUs are contingent rights, vesting after one year of continuous service, that will entitle him to either one share of common stock or a cash payment equivalent to the fair market value of one share. Following this transaction, Hume directly holds 8,325 STUs, which are not open-market purchases but rather derivative awards linked to the company's financial incentive plan.
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data
TG Therapeutics (TGTX) stock has rallied for eight consecutive sessions following positive early clinical data for a new subcutaneous version of its Briumvi drug in myasthenia gravis patients. The company also reported strong Q1 2026 revenue of $205 million, driven by Briumvi sales, and raised its full-year sales forecast to $925 million. Analysts are largely bullish on TGTX, with seven of nine rating it ‘Buy’ or higher.
TG Therapeutics (TGTX) Stock Looks 14% Overvalued as BRIUMVI Launch Hopes Face Off With Momentum
TG Therapeutics (TGTX) stock is currently considered 14% overvalued at $50.54, with a fair value estimated at $44.43 per share, despite recent strong performance. The potential launch of subcutaneous BRIUMVI is a significant catalyst that could expand its market reach, but the company faces concentration risk in BRIUMVI and increasing competition. While the analyst narrative suggests overvaluation, the stock's current P/E ratio of 15.5x is lower than the US Biotech average and a fair ratio of 21.5x, presenting mixed signals for investors.
TG Therapeutics (TGTX) Stock Looks 14% Overvalued as BRIUMVI Launch Hopes Face Off With Momentum
TG Therapeutics (TGTX) stock is currently viewed as 14% overvalued, trading at $50.54 against a fair value of $44.43. While the planned launch of subcutaneous BRIUMVI is a significant growth catalyst, expanding its market reach, the company faces concentration risk and rising competition. The P/E ratio presents a different perspective, suggesting potential upside if the market shifts towards a higher fair ratio.
TG Therapeutics Stock On Fire: Up 26% With 7-Day Winning Streak
The article reports that TG Therapeutics stock is experiencing a significant surge, with a 26% increase and a seven-day winning streak. This indicates strong positive momentum for the company's shares.
Director Sagar Lonial receives 8,325 stock tracking units at TG Therapeutics (TGTX)
TG Therapeutics director Sagar Lonial was granted 8,325 stock tracking units (STUs) as part of an equity-based compensation award. These units represent a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share. The STUs will vest on the first anniversary of the grant date, provided Lonial remains in continuous service with the company.
Director at TG Therapeutics (TGTX) granted 8,325 stock tracking units
TG Therapeutics director Laurence N. Charney was granted 8,325 Stock Tracking Units on June 11, 2026, as compensation. These units, which have no exercise price, represent a contingent right to receive either one share of common stock or an equivalent cash payment after a one-year vesting period. This transaction is an equity-based incentive and not an open-market trade, with Charney holding 8,325 units directly following the award.
[Form 4] TG THERAPEUTICS, INC. Insider Trading Activity
Kenneth Hoberman, a director of TG Therapeutics, Inc. (TGTX), reported a grant of 8,325 Stock Tracking Units (STUs) on June 11, 2026, as per a recent Form 4 filing. These STUs represent a contingent right to receive either one share of common stock or an equivalent cash payment, vesting on the first anniversary of the grant date if Hoberman remains in continuous service. This is considered a routine equity compensation award rather than a market transaction, designed to align the director's incentives with the company's long-term performance.
TG Therapeutics (TGTX) soars 7.5%: Is further upside left in the stock?
TG Therapeutics (TGTX) stock recently surged by 7.5%. The article likely discusses the factors contributing to this price increase and analyzes whether the company has further potential for growth and upside in its stock value.
TG Therapeutics Shareholders Reject Executive Compensation at Meeting
TG Therapeutics shareholders rejected an advisory proposal on executive compensation at their 2026 Annual Meeting, signaling dissatisfaction with current pay practices and potentially prompting a reassessment by the board. Despite this, shareholders elected six directors and ratified KPMG LLP as the independent accounting firm. TipRanks' AI Analyst, Spark, rated TGTX as "Outperform" due to strong profitability, a clean balance sheet, and positive earnings.
5-Day Rally Sends TG Therapeutics Stock Up 23%
TG Therapeutics stock has experienced a significant 23% rally over the past five days. The article title highlights this strong short-term performance for the company.
TG Therapeutics (TGTX) Is Up 18.5% After Positive Subcutaneous BRIUMVI Phase 1 Data Is Released
TG Therapeutics (TGTX) has seen an 18.5% increase after reporting positive Phase 1 data for its high-concentration subcutaneous BRIUMVI in relapsing multiple sclerosis. The data indicates that subcutaneous administration could enable at-home dosing via autoinjector while maintaining efficacy comparable to intravenous infusions. This development strengthens TG Therapeutics' investment narrative, with a key Phase 3 readout expected in late 2026 or early 2027.
TG Therapeutics Shareholders Reject Executive Compensation at Meeting
At its 2026 Annual Meeting, TG Therapeutics' shareholders elected six directors and ratified KPMG as the independent auditor. However, investors rejected the advisory proposal on executive compensation, indicating dissatisfaction with current pay practices. This decision highlights shareholder concerns regarding governance and may prompt the board to re-evaluate executive pay structures.
Shareholders at TG Therapeutics (NASDAQ: TGTX) reject 2026 executive pay
At TG Therapeutics' 2026 Annual Meeting, shareholders rejected the advisory vote on executive compensation, with 48,858,169 votes against and 31,905,837 for. While directors were re-elected and KPMG LLP was ratified as the independent auditor, the "say-on-pay" outcome signals significant shareholder dissatisfaction with executive compensation. This non-binding vote is expected to prompt the board to review pay structures and engage with shareholders.
TGTX rises on positive phase I data for subcutaneous Briumvi in MG
TG Therapeutics (TGTX) saw its shares rise after announcing positive topline results from its Phase 1 study of subcutaneous Briumvi (ublituximab) for the treatment of Myasthenia Gravis (MG). The study met its primary endpoint, demonstrating that the subcutaneous formulation achieved comparable exposure and bioequivalence to the intravenous formulation at 24 hours post-dose. These results support the potential for a more convenient subcutaneous self-administration option for patients with MG.
TG Therapeutics (TGTX) Is Up 18.5% After Positive Subcutaneous BRIUMVI Phase 1 Data Is Released
TG Therapeutics (TGTX) reported positive Phase 1 data for a high-concentration subcutaneous formulation of BRIUMVI for relapsing multiple sclerosis, showing comparable pharmacokinetic, pharmacodynamic, safety, and tolerability results to the approved intravenous version. This development supports ongoing Phase 3 trials and suggests potential for at-home administration via an autoinjector. The news bolsters the investment narrative for TG Therapeutics, particularly ahead of the subcutaneous BRIUMVI Phase 3 readout expected in late 2026 or early 2027.
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates
TG Therapeutics (TGTX) stock has surged over 8.58% following positive clinical trial data for its anti-CD20 therapy, Briumvi. Key catalysts include Phase 3 ENHANCE data showing bioequivalence with a simpler single-dose regimen, strong Phase 1 subcutaneous Briumvi data supporting at-home administration, and positive early results in myasthenia gravis, expanding its potential market. The company reports strong financials with significant revenue, high margins, and profitability, making it an attractive prospect for momentum traders despite the inherent volatility of biotech stocks.
TG Therapeutics stock hits 52-week high at 44.7 USD
TG Therapeutics (TGTX) stock has reached a new 52-week high of $44.70, currently trading at $45.16. The stock has seen significant year-to-date and six-month gains of 45% and 42% respectively, with InvestingPro analysis suggesting it is undervalued. Despite strong market performance, the company recently reported a Q1 2026 EPS miss and slightly lower-than-expected revenue, though it has announced positive clinical trial updates for its drug BRIUMVI.
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
TG Therapeutics (TGTX) shares dropped 16% following a disappointing Q2 earnings report, despite the company reaffirming its strong confidence in its multiple sclerosis drug, ublituximab. The decline was attributed to higher-than-expected expenses, although the drug's FDA approval decision is anticipated by year-end. Management expressed optimism for ublituximab's market potential and impact on patient care.
A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones
TG Therapeutics (TGTX) is gaining attention due to positive clinical data and formulation updates for its drug BRIUMVI, leading to a significant increase in its share price. Despite recent gains, the stock is considered slightly undervalued by analysts, with a key future growth driver being the planned launch of a subcutaneous BRIUMVI formulation. Investors are encouraged to review the company's detailed analysis to understand the valuation and potential risks.
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
TG Therapeutics (NASDAQ: TGTX) saw its stock drop 16% following a disappointing second-quarter earnings report, which included an earnings per share miss and a slight revenue beat. Despite the financial setback, the company reiterated its strong confidence in ublituximab, its multiple sclerosis drug candidate, highlighting positive Phase 3 trial results and strategic plans for its ongoing development and potential future approval.
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
TG Therapeutics announced positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis (MG) patients, showing an 82% achievement of Minimal Clinically Important Difference (MCID) in MG-ADL. The company also initiated a potentially registration-directed Phase 2 trial. This trial will evaluate BRIUMVI as a maintenance therapy following efgartigimod induction, aiming to combine rapid symptom control with sustained disease modification.
Why Is TG Therapeutics Stock Gaining Tuesday?
TG Therapeutics (NASDAQ: TGTX) stock rose on Tuesday following positive topline Phase 1 data for its subcutaneous BRIUMVI for myasthenia gravis, showing significant improvement in MG-ADL scores. The company plans a Phase 2 trial and intends to submit a supplemental FDA application in the latter half of 2026 for a consolidated single infusion regimen for relapsing forms of multiple sclerosis, based on earlier positive Phase 3 trial results. Technically, the stock remains in an uptrend, holding above key moving averages despite a recent cooling in momentum.
